Skip to main content
Signal8
Launch Terminal

CAPRICOR THERAPEUTICS, INC. (CAPR)

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Capricor Therapeutics, Inc. logo

Capricor Therapeutics, Inc.

NASDAQ:CAPRHealthcare
-3.77%$6.38
AH$6.92+8.46%vs close
Mkt Cap$370.93M
Float41.01M
O/S58.14M
Vol
$ Vol
RVOL
Inst Own67.6%
SI48.4%
Earnings
Dilution
Capricor Therapeutics, Inc. logoNASDAQ:CAPR$6.38-3.77%
Upcoming Catalysts
  • deramiocelPDUFA
    Duchenne muscular dystrophy (DMD)
    was Aug 22, 2026
    Cash runway at this date: 20mo
    Nov 22, 2026in 20 daysPR
  • Deramiocel (CAP-1002)PDUFA
    Duchenne muscular dystrophy
    Cash runway at this date: 20mo
    Nov 22, 2026in 20 days8-K
Phase Distribution
16 lead-sponsored trials·2 active·11 completed
Phase 14
Phase 1/22
Phase 28
Phase 31
Not applicable1
(1 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Active, not recruiting

    A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

    Deramiocel (CAP-1002), Placebo

    Muscular Dystrophies, Muscular Dystrophy, Duchenne +6

    Enrollment
    106
    Start
    Jun 2022
    Primary Completion
    Jun 2025
    Completion
    Mar 2027est.
    NCT05126758
  • Phase 2
    Completed

    Study to Assess Hemodynamic Effects, Safety and Tolerability of Chimeric Natriuretic Peptide (CD-NP) in Patients With Stabilized Acute Heart Failure (AHF)

    CD-NP (Chimeric natriuretic peptide)

    Acute Decompensated Heart Failure

    Enrollment
    30
    Start
    Jun 2008
    Primary Completion
    Dec 2008
    Completion
    Dec 2008
    NCT00699712
  • Phase 2
    Completed

    Study to Assess the Safety and Efficacy of CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure

    CD-NP

    Acute Decompensated Heart Failure

    Enrollment
    77
    Start
    Jun 2009
    Primary Completion
    Jun 2010
    Completion
    Jul 2010
    NCT00839007
  • Phase 2
    Completed

    Safety Study of Cenderitide in Stable Chronic Heart Failure

    Cenderitide

    Heart Failure

    Enrollment
    14
    Start
    Jan 2015
    Primary Completion
    Apr 2015
    Completion
    Apr 2015
    NCT02359227
  • Phase 2
    Completed

    HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)

    Allogeneic Cardiosphere-Derived Cells (CAP-1002)

    Duchenne Muscular Dystrophy, Cardiomyopathy

    Enrollment
    25
    Start
    Jan 2016
    Primary Completion
    Sep 2017
    Completion
    Sep 2017
    NCT02485938
  • Phase 2
    Completed

    A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

    CAP-1002, Placebo

    Muscular Dystrophies, Muscular Dystrophy, Duchenne +6

    Enrollment
    20
    Start
    Apr 2018
    Primary Completion
    Mar 2020
    Completion
    Mar 2020
    NCT03406780
  • Phase 2
    Active, not recruiting

    Open-label Extension of the HOPE-2 Trial

    Deramiocel (CAP-1002)

    Duchenne Muscular Dystrophy

    Enrollment
    13
    Start
    Aug 2020
    Primary Completion
    Feb 2022
    Completion
    Mar 2027est.
    NCT04428476
  • Phase 2
    Completed

    Intravenous Infusion of CAP-1002 in Patients With COVID-19

    CAP-1002, Placebo

    Covid19

    Enrollment
    55
    Start
    Nov 2020
    Primary Completion
    Feb 2022
    Completion
    Feb 2022
    NCT04623671
  • Phase 2
    Completed

    Halt cardiomyOPathy progrEssion in Duchenne (HOPE-OLE)

    Allogeneic Cardiosphere-Derived Cells (CAP-1002)

    Duchenne Muscular Dystrophy

    Enrollment
    8
    Start
    Jun 2018
    Primary Completion
    Mar 2019
    Completion
    Mar 2019
    NCT06304064
  • Phase 1/2
    Terminated

    Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration

    CAP-1002 Allogeneic Cardiosphere-Derived Cells, Placebo

    Myocardial Infarction

    Enrollment
    135
    Start
    Nov 2012
    Primary Completion
    Jul 2017
    Completion
    Feb 2019
    NCT01458405
  • Phase 1/2
    Completed

    Safety Study of Cenderitide in Chronic Stable Heart Failure With Moderate Renal Impairment

    Cenderitide, Placebo

    Heart Failure, Renal Insufficiency

    Enrollment
    8
    Start
    Dec 2015
    Primary Completion
    Mar 2016
    Completion
    Mar 2016
    NCT02603614
  • Phase 1
    Completed

    Safety and Pharmacodynamic Study of CD-NP

    CD-NP

    Heart Failure, Congestive

    Enrollment
    22
    Start
    Jan 2007
    Primary Completion
    -
    Completion
    May 2007
    NCT00482937
  • Phase 1
    Completed

    Safety Study of CD-NP in Heart Failure

    CD-NP

    Congestive Heart Failure

    Enrollment
    20
    Start
    Nov 2007
    Primary Completion
    -
    Completion
    Dec 2008
    NCT00557661
  • Phase 1
    Completed

    PK/PD Study of Subcutaneous Cenderitide Infusion in CHF Patients

    Cenderitide

    Heart Failure, ADHF +2

    Enrollment
    58
    Start
    May 2011
    Primary Completion
    Oct 2011
    Completion
    Nov 2011
    NCT01316432
  • Phase 1
    Unknown status

    Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells (DYNAMIC)

    Allogeneic Cardiosphere-Derived Cells (CDCs)

    Dilated Cardiomyopathy (DCM), Ischemic Cardiomyopathy +2

    Enrollment
    42
    Start
    Nov 2014
    Primary Completion
    May 2015
    Completion
    Apr 2020est.
    NCT02293603
  • Expanded access
    No longer available

    CAP-1002 in Severe COVID-19 Disease

    CAP-1002 Allogeneic Cardiosphere-Derived Cells

    COVID-19

    Enrollment
    -
    Start
    -
    Primary Completion
    -
    Completion
    -
    NCT04338347
Search ClinicalTrials.gov for “Capricor Therapeutics”